Support for ODM from Largest Ever Intra-Op Haemodynamic RCT

The British Journal of Anaesthesia (BJA) has published a new study, the largest ever positive Randomised Clinical Trial (RCT) on Goal-Directed Haemodynamic Therapy(GDHT) using Deltex Medical’s ODM system. The results demonstrate that even surgical patients considered to be at low to medium risk benefit significantly from having GDHT using ODM. (GDHT as opposed to Goal-Directed Fluid Therapy (GDFT) offers a protocol that combines both fluid and drugs).

The paper concludes that monitoring all low-medium risk patients with ODM, then intervening with the right technology significantly reduces post-op complications, improving patient safety and saving money.

The newly published 420 patient study was conducted in Spain and funded by the Spanish Government. It was a prospective, multi-centre, randomised clinical trial aimed at evaluating the impact of ODM-guided administration of intravenous (IV) fluids and vasoactive drugs on post-operative complications following major surgery. Importantly, researchers performing patient evaluations were blinded to the treatment.

The paper is entitled “Effect of goal-directed haemodynamic therapy on postoperative complications in low-moderate risk surgical patients: a multicentre randomised controlled trial” (FEDORA trial).

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    Deltex Medical Group plc in a strong financial position

    Nigel Keen, Chairman of Deltex Medical, commented: “The successful £2,050,000 fund raising in February 2018 has put the Group in a stronger financial position – allowing us to improve our business structure. “We made a number

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group New CEO Andy Mears

    Deltex Medical Group Plc (LON:DEMG) New CEO Andy Mears talks to DirectorsTalk about his new position. Andy talks about his background, how he thinks Deltex is positioned, his plans for the next 12 months and the

    Deltex Medical Group Plc

    Deltex Medical Group plc New Chief Executive

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, announced today that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect. Mr. Phillips recently approached Deltex’s

    Deltex Medical Group Plc

    Another Successful Learning Event Sponsored by Deltex

    May 28th saw Deltex Medical Group supporting Current Initiatives, Research and the Role of Haemodynamic Monitoring at London’s Montague Hotel. Held under the auspices of the EBPOM organisation (Evidence Based PeriOperative Medicine), the congress saw keynote presentations from

    Deltex Medical Group Plc

    CEO Q&A with Ewan Phillips at Deltex Medical Group plc (LON:DEMG)

    Deltex Medical Group’s Ewan Phillips discusses their full year results, what’s been happening operationally, their strategy for the next 12 months and what investors should look forward to in the near future in this exclusive interview with DirectorsTalk

    Deltex Medical Group Plc

    Deltex Medical Group PLC Investor Event

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), today announced that it will be hosting an investor event on 22 May 2018 following the publication of its full year results for

    Deltex Medical Group Plc

    Deltex Sponsoring Evidence-Based Clinical Event

    Deltex Medical will be supporting a forthcoming congress in London on May 28th. Current Initiatives, Research and the Role of Hemodynamic Monitoring is free to attend for clinicians and healthcare providers who are interested in the principles and

    Deltex Medical Group Plc

    Critical caring

    It takes a plethora of products and people to provide patients premium protection. Changing payment models, the digitization of healthcare and the need to deliver higher quality care at a lower cost are driving significant change